PERAN PROTEIN SIKLIN DALAM REGULASI SIKLUS SEL DAN IMPLIKASINYA TERHADAP PENYAKIT: SUATU TINJAUAN LITERATUR

Suharni Suharni

doi:10.59003/nhj.v6i1.2220

Authors

Suharni Suharni Universitas Baiturrahmah

DOI:

https://doi.org/10.59003/nhj.v6i1.2220

Keywords:

cyclin proteins, cyclin-dependent kinases, cell cycle, checkpoint, cancer, CDK4/6 inhibitors.

Abstract

The cell cycle is a biological process that regulates growth, genetic replication, and cell division in a coordinated manner to maintain tissue homeostasis. Regulation of this process depends on the integrated interactions between cyclin proteins (cyclins), cyclin-dependent kinases (CDKs), cyclin-dependent kinase inhibitors (CKIs), and various checkpoint proteins. Cyclin proteins function as master regulators, specifically activating CDKs at each phase of the cell cycle, ensuring the orderly transitions between G1, S, G2, and M phases. The activity of the cyclin-CDK complex is controlled through mechanisms of synthesis, degradation by the ubiquitin-proteasome system, and checkpoint surveillance, ensuring accurate DNA replication and cell division. Disruption of this system leads to uncontrolled cell proliferation, genomic instability, checkpoint failure, and an increased risk of various diseases, particularly cancer. In addition to its role in oncogenesis, dysregulation of cyclin proteins is also associated with cellular aging, impaired tissue regeneration, and several neurodegenerative diseases. Advances in molecular biology have made the cyclin-CDK pathway a key target for precision therapy, as evidenced by the successful development of CDK4/6 inhibitors in various cancers. This review article discusses the regulatory mechanisms of cyclin proteins in the cell cycle, their roles at each phase of cell division, the clinical implications of dysregulation, and the development of targeted therapies based on current scientific evidence.

Downloads

Download data is not yet available.

References

Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., & Walter, P. (2015). Molecular Biology of the Cell (6th ed.). Garland Science.

Lodish, H., Berk, A., Kaiser, C. A., et al. (2016). Molecular Cell Biology (8th ed.). W.H. Freeman.

Morgan, D. O. (2007). The Cell Cycle: Principles of Control. New Science Press.

Urry, L. A., Cain, M. L., Wasserman, S. A., Minorsky, P. V., & Orr, R. B. (2020). Campbell Biology (12th ed.). Pearson.

Finn, R. S., et al. (2016). Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine, 375, 1925–1936.

Hwang, H. C., & Clurman, B. E. (2005). Cyclin E in normal and neoplastic cell cycles. Oncogene, 24, 2776–2786.

Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: A changing paradigm. Nature Reviews Cancer, 9, 153–166.

Pines, J. (2011). Cubism and the cell cycle. Nature Reviews Molecular Cell Biology, 12, 427–438.

Reed, S. I. (2003). Ratchets and clocks: The cell cycle, ubiquitylation and protein turnover. Nature Reviews Molecular Cell Biology, 4, 855–864.

Sherr, C. J., & Roberts, J. M. (1999). CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes & Development, 13, 1501–1512.

Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003). The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferation, 36(3), 131–149.

Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022). Cell cycle control in cancer. Nature Reviews Molecular Cell Biology, 23, 74–88.

Nurse, P. (2024). The discovery of cyclin-dependent kinases. Nature Reviews Molecular Cell Biology, 25, 763.

Pellarin, I., Dall’Acqua, A., Favero, A., et al. (2025). Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, 10, 11.

Asciolla, J. J., Wu, X., Adamopoulos, C., et al. (2025). Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer. Nature Cancer, 6, 24–40.

Shanabag, A., Armand, J., Son, E., et al. (2025). Targeting CDK4/6 in breast cancer. Experimental & Molecular Medicine, 57, 312–322.

Marei, H. E., Bedair, K., Hasan, A., et al. (2025). Targeting CDKs in cancer therapy: Advances in PROTACs and molecular glues. npj Precision Oncology, 9, 204.

Gong, Y., & Li, H. (2024). CDK7 in breast cancer: Mechanisms of action and therapeutic potential. Cell Communication and Signaling, 22, 226.

Csergeová, L., Krbušek, D., & Janoštiak, R. (2024). CIP/KIP and INK4 families as hostages of oncogenic signaling. Cell Division, 19, 11.

Karimbayli, J., Pellarin, I., Belletti, B., et al. (2024). Insights into the structural and functional activities of PCTAIRE CDKs. Molecular Cancer, 23, 135.

Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., & Walter, P. (2015). Molecular Biology of the Cell (6th ed.). Garland Science.

Cavalu, S., Abdelhamid, A. M., Saber, S., et al. (2024). Cell cycle machinery in oncology: A comprehensive review of therapeutic targets. The FASEB Journal, 38, e23734. https://doi.org/10.1096/fj.202400769R

Finn, R. S., Martin, M., Rugo, H. S., et al. (2016). Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine, 375(20), 1925–1936.

Hwang, H. C., & Clurman, B. E. (2005). Cyclin E in normal and neoplastic cell cycles. Oncogene, 24(17), 2776–2786.

Lee, C. F., Pienta, K. J., & Amend, S. R. (2024). The involvement of cyclin-dependent kinase 7 (CDK7) and 9 (CDK9) in coordinating transcription and cell cycle checkpoint regulation. Cell Cycle, 23(21–24), 962–974.

Lodish, H., Berk, A., Kaiser, C. A., et al. (2016). Molecular Cell Biology (8th ed.). W. H. Freeman.

Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: A changing paradigm. Nature Reviews Cancer, 9(3), 153–166.

Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022). Cell cycle control in cancer. Nature Reviews Molecular Cell Biology, 23, 74–88.

Morgan, D. O. (2007). The Cell Cycle: Principles of Control. New Science Press.

M. J., McKenzie, J. E., Bossuyt, P. M., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology, 134, 178–189. https://doi.org/10.1016/j.jclinepi.2021.03.001

Nurse, P. (2024). The discovery of cyclin-dependent kinases. Nature Reviews Molecular Cell Biology, 25, 763.

Pellarin, I., Dall'Acqua, A., Favero, A., et al. (2025). Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, 10, 11.

Pines, J. (2011). Cubism and the cell cycle. Nature Reviews Molecular Cell Biology, 12(7), 427–438.

Reed, S. I. (2003). Ratchets and clocks: The cell cycle, ubiquitylation and protein turnover. Nature Reviews Molecular Cell Biology, 4(11), 855–864.

Sherr, C. J., & Roberts, J. M. (1999). CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes & Development, 13(12), 1501–1512.

Urry, L. A., Cain, M. L., Wasserman, S. A., Minorsky, P. V., & Orr, R. B. (2020). Campbell Biology (12th ed.). Pearson.

Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003). The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferation, 36(3), 131–149.

Asciolla, J. J., Wu, X., Adamopoulos, C., et al. (2025). Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer. Nature Cancer, 6, 24–40.

Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment. (2025). Chinese Journal of Natural Medicines, 23(3), 286–298.